PLA2G15

Across TCGA pan-cancer cohorts, PLA2G15 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PLA2G15 data layer compared with 28 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PLA2G15 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PLA2G15 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

CCRCC, LSCC, and LUAD are the cancer types where PLA2G15 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	III,IV	0.401	0.807	.006	10	view →
LSCC	OS	Median	III,IV	0.918	0.498	.003	5	view →
LUAD	DFS	Median	II,III,IV	0.642	0.366	.021	5	view →
PDAC	OS	Quartile	II,III,IV	0.225	0.414	.013	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PLA2G15–CCRCC (DFS)

Open the CCRCC breakdown →